Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Quisinostat
108
CHF
CHF 108.00
In stock
SYN-3029-M0011 mgCHF 108.00
SYN-3029-M0055 mgCHF 215.00
SYN-3029-M01010 mgCHF 383.00
SYN-3029-M05050 mgCHF 1'017.00
SYN-3029-M100100 mgCHF 1'664.00
| Product Details | |
|---|---|
| Synonyms | JNJ-26481585 |
| Product Type | Chemical |
| Properties | |
| Formula | C21H26N6O2 |
| MW | 394.5 |
| CAS | 875320-29-9 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data | Target: HDAC1, 2, 4, 10 and HDAC11 | Kinase Group: N/A | Substrate: N/A |
| InChi Key | PAWIYAYFNXQGAP-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Quisinostat (JNJ-26481585) is a novel second-generation panHDAC inhibitor of HDAC1, 2, 4, 10 and 11. Its highest potency is against HDAC1 with an IC50 of 0.11nM. It has only modest potency against HDACs 2, 4, 10, and 11 (IC50 ranging from 0.33nM to 0.64nM). It has low activity against HDACs 3, 5, 8, and 9 and its lowest potency is against HDACs 6 and 7.
Product References
- JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity: J. Arts, et al.; Clin. Cancer Res. 15, 6841 (2009)
- Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585: T. Stuehmer, et al.; Br. J. Haematol. 149, 529 (2010)
Related Products
